Determining Cardiometabolic and Antioxidant Effects of Olive Leaf Extract in Patients with Essential Hypertension

Yaghoobzadeh, Hayedeh; Mehravar, Sepideh; Javadi, H.; Memarzadeh, Mohammad Reza; Mirhashemi, Seyyed Mehdi

doi:10.32598/jqums.23.5.372

Cited by 5 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The five trials included in this review ( Javadi et al, 2019 ; Perrinjaquet-Moccetti et al, 2008 ; Susalit et al, 2011 ; Wong et al, 2014 ; Yaghoobzadeh et al, 2020 ) had met the eligibility criteria. One trial included monozygotic twins with untreated suboptimal blood pressure, exceeding 120 mmHg systolic or 80 mmHg diastolic at rest ( Perrinjaquet-Moccetti et al, 2008 ).…”

Section: Resultsmentioning

confidence: 99%

“…One trial included participants with hypertension and exclusions were hypertensive patients who had complications such as diabetes, kidney disease, and hypo and/or hyperthyroidism ( Javadi et al, 2019 ). One trial included patients with essential hypertension ( Yaghoobzadeh et al, 2020 ). Two trials had declared funding from olive leaf extract manufacturers ( Perrinjaquet-Moccetti et al, 2008 ; Susalit et al, 2011 ; Wong et al, 2014 ).…”

Section: Resultsmentioning

confidence: 99%

“…Two trials were conducted in high-income countries ( Perrinjaquet-Moccetti et al, 2008 ; Wong et al, 2014 ) and three trials were conducted in moderate-income countries ( Javadi et al, 2019 ; Susalit et al, 2011 ; Yaghoobzadeh et al, 2020 ). Three trials recruited patients from healthcare settings ( Javadi et al, 2019 ; Susalit et al, 2011 ; Yaghoobzadeh et al, 2020 ) and two trials recruited patients from a research institute ( Perrinjaquet-Moccetti et al, 2008 ; Wong et al, 2014 ). Two trials reported the exclusion of participants due to hypertension with complications, such as diabetes mellitus, kidney disease, and heart disease ( Javadi et al, 2019 ; Susalit et al, 2011 ).…”

Section: Resultsmentioning

confidence: 99%

“…Trial participants were randomized regarding intervention and control groups. Olive leaf extract was given in 1,000 mg ( Susalit et al, 2011 ; Wong et al, 2014 ) and 500 mg per day doses ( Javadi et al, 2019 ; Perrinjaquet-Moccetti et al, 2008 ; Yaghoobzadeh et al, 2020 ). For the 1,000 mg per day dose, one trial used a combined formulation of 500 mg olive leaf extract with green coffee bean extract and beetroot tablet to be taken twice daily ( Wong et al, 2014 ) and one trial used a 500 mg olive leaf extract tablet twice daily ( Susalit et al, 2011 ).…”

Section: Resultsmentioning

confidence: 99%

“…For the 1,000 mg per day dose, one trial used a combined formulation of 500 mg olive leaf extract with green coffee bean extract and beetroot tablet to be taken twice daily ( Wong et al, 2014 ) and one trial used a 500 mg olive leaf extract tablet twice daily ( Susalit et al, 2011 ). For the 500 mg per day dose, one trial used the olive leaf extract 500 mg tablet once daily ( Perrinjaquet-Moccetti et al, 2008 ) and two trials used the 250 mg olive leaf extract tablet twice daily ( Javadi et al, 2019 ; Yaghoobzadeh et al, 2020 ). Three trials used a placebo as a control ( Javadi et al, 2019 ; Wong et al, 2014 ; Yaghoobzadeh et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Olive leaf extract effect on cardiometabolic profile among adults with prehypertension and hypertension: a systematic review and meta-analysis

Ismail

Norhayati

Mohamad

2021

PeerJ

View full text Add to dashboard Cite

Background This systematic review and meta-analysis aimed to determine the effectiveness of olive leaf extract on cardiometabolic profiles among prehypertensive and hypertensive groups. Methodology The Cochrane central register of controlled trials, Medline (1966 to April week 1, 2020), Embase (1966 to April week 1, 2020) and trial registries for relevant randomized clinical trials were used. Published and unpublished randomized clinical trials were reviewed and evaluated. Random effects models were used to estimate the continuous outcomes and mean differences (MDs); both with 95% confidence intervals (CIs). The primary outcomes were changes in systolic and diastolic BP. The secondary outcomes were changes in lipid profile, glucose metabolism, inflammatory markers for CVD, kidney and liver functions safety parameters. We assessed the data for risk of bias, heterogeneity, sensitivity, reporting bias and quality of evidence. Results Five trials were included involving 325 patients aged 18–80 years. Two trials involved high-income countries and three trials involved moderate-income countries. The analysis performed was based on three comparisons. No significant changes were found between systolic or diastolic blood pressure (BP) for the first comparison, 1,000 mg per day for a combined formulation of olive leaf extract versus a placebo. The second comparison, 500 mg per day of olive leaf extract versus placebo or no treatment, showed a significant reduction in systolic BP over a period of at least 8 weeks of follow up (MD −5.78 mmHg, 95% CI [−10.27 to −1.30]) and no significant changes on diastolic BP. The third comparison, 1,000 mg per day of olive leaf extract versus placebo shows no significant difference but an almost similar reduction in systolic BP (−11.5 mmHg in olive leaf extract and −13.7 mmHg in placebo, MD 2.2 mmHg, 95% CI [−0.43–4.83]) and diastolic BP (−4.8 mmHg in olive leaf extract and −6.4 mmHg in placebo, MD 1.60 mmHg, 95% CI [−0.13–3.33]). For secondary outcomes, 1,000 mg per day of olive leaf extract versus captopril showed a reduction in LDL (MD −6.00 mg/dl, 95% CI [−11.5 to −0.50]). The 500 mg per day olive leaf extract versus placebo showed a reduction in inflammatory markers for CVD IL-6 (MD −6.83 ng/L, 95% CI [−13.15 to −0.51]), IL-8 (MD −8.24 ng/L, 95% CI [−16.00 to −0.48) and TNF-alpha (MD −7.40 ng/L, 95% CI [−13.23 to −1.57]). Conclusions The results from this review suggest the reduction of systolic BP, LDL and inflammatory biomarkers, but it may not provide a robust conclusion regarding the effects of olive leaf extract on cardiometabolic profile due to the limited number of participants in the included trials. Review registrations PROSPERO CDR 42020181212.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Olive leaf extract effect on cardiometabolic profile among adults with prehypertension and hypertension: a systematic review and meta-analysis

Ismail

Norhayati

Mohamad

2021

PeerJ

View full text Add to dashboard Cite

show abstract

Olive leaf extract effect on cardiometabolic risk factors: a systematic review and meta-analysis of randomized clinical trials

Álvares,

Garcêz,

Silva

et al. 2024

Nutrition Reviews

View full text Add to dashboard Cite

Context Olive leaf extract (OLE) is rich in phenolic compounds, which are known for their health benefits. Cardiovascular diseases, primarily coronary heart disease and stroke, are leading causes of mortality globally. Objective This systematic review aimed to assess the impact of OLE on cardiometabolic risk factors in adults. The selection of studies was based on intervention and outcomes, using relevant search descriptors. Data Sources The databases PubMed, EMBASE, and Web of Science were systematically searched for pertinent studies published up to August 2021. Data Extraction Only randomized clinical trials, either cross-over or parallel, involving adult individuals aged ≥18 years, were considered. Additionally, trials that had a comparative or placebo group and used pure OLEs for oral treatment were included. Data Analysis Twelve randomized clinical trials (RCTs) met the inclusion criteria. These trials had follow-up periods ranging from 2 days to 12 weeks and involved 703 patients aged 18 years–79 years. The outcomes demonstrated a positive correlation between the intervention group and glucose metabolism (4 RCTs), blood pressure (2 RCTs), lipid profile (2 RCTs), and inflammatory markers (2 RCTs). The RoB2 tool and the GRADE system were used to evaluate the risk of bias and the quality of evidence in the studies. Conclusions In the meta-analysis, fasting glycemia, as evaluated in studies using a low dose of OLE, showed a significant result favoring the control group. To obtain more consistent results, further clinical studies in humans, using similar methodologies, are required. Systematic Review Registration PROSPERO registration no. CRD42020200877.

show abstract

The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials

Razmpoosh

Abdollahi

Mousavirad

et al. 2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background The aim of this systematic review and meta-analysis was to determine the effect of olive leaf extract (OLE) supplementation on cardiovascular-related variables, including lipid, glycemic, inflammatory, liver and renal-related factors, as well as blood pressure. Methods PubMed, ISI Web of Science, Scopus, and Cochrane library were searched, up to October 2021, for relevant controlled trials. Mean differences and standard deviations were pooled for all outcomes, using a random-effects model. The methodological quality, as well as quality of evidence were assessed using standard tools. Results Twelve studies (n = 819 participants) were included in our analyses. Overall analyses showed that OLE supplementation significantly decreased triglyceride (TG) levels (WMD = − 9.51 mg/dl, 95% CI − 17.83, − 1.18; P = 0.025; I2 = 68.7%; P-heterogeneity = 0.004), and systolic blood pressure (SBP) (WMD = − 3.86 mmHg, 95% CI − 6.44, − 1.28 mmHg; P = 0.003; I2 = 19.9%; P-heterogeneity = 0.28). Subgroup analyses also revealed a significant improvement in SBP (− 4.81 mmHg) and diastolic blood pressure (− 2.45 mmHg), TG (− 14.42 mg/dl), total cholesterol (TC) (− 9.14 mg/dl), and low-density lipoprotein-C (LDL-C) (− 4.6 mg/dl) measurements, in patients with hypertension. Significant reductions were also observed in TC (− 6.69 mg/dl), TG (− 9.21 mg/dl), and SBP (− 7.05 mmHg) in normal-weight individuals. However, no meaningful changes were seen in glucose hemostasis, liver and kidney, or inflammatory markers. Conclusion The present study revealed that supplementation with OLE yielded beneficial effects for blood pressure and lipid profile in adults, especially in patients with hypertension. As the quality of evidence for glucose hemostasis variables, liver, kidney, and inflammatory markers, were low-to-very low, higher quality RCTs may impact the overarching results. This study was registered at PROSPERO with the code CRD42022302395.

show abstract

Determining Cardiometabolic and Antioxidant Effects of Olive Leaf Extract in Patients with Essential Hypertension

Cited by 5 publications

References 22 publications

Olive leaf extract effect on cardiometabolic profile among adults with prehypertension and hypertension: a systematic review and meta-analysis

Olive leaf extract effect on cardiometabolic profile among adults with prehypertension and hypertension: a systematic review and meta-analysis

Olive leaf extract effect on cardiometabolic risk factors: a systematic review and meta-analysis of randomized clinical trials

The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About